Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-210292
Filing Date
2026-05-07
Accepted
2026-05-07 07:04:48
Documents
60
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q amlx-20260331.htm   iXBRL 10-Q 2214715
2 EX-31.1 amlx-ex31_1.htm EX-31.1 17601
3 EX-31.2 amlx-ex31_2.htm EX-31.2 17593
4 EX-31.3 amlx-ex31_3.htm EX-31.3 17593
5 EX-32.1 amlx-ex32_1.htm EX-32.1 9751
6 EX-32.2 amlx-ex32_2.htm EX-32.2 9749
7 EX-32.3 amlx-ex32_3.htm EX-32.3 9748
  Complete submission text file 0001193125-26-210292.txt   6955770

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20260331.xsd EX-101.SCH 880703
64 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20260331_htm.xml XML 946530
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142 617-682-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41199 | Film No.: 26950795
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)